Anna Cramer
Family · Scottsdale, AZNPI 1124507785
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,583 of the $14,274 with a category attached, or 67.1%. 19 manufacturers reported payments, led by Eli Lilly at 36.3% of the total. Reporting peaked in 2023 at $8,072 and has fallen 95.8% since, to $341 in 2025. Among family clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $132.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$5K
- AbbVie$4K
- Takeda Pharmaceuticals U.S.A., Inc.$703
- Gilead$673
- E.r. Squibb & Sons, L.L.C.$608
- Lilly USA, LLC$556
- plus $3K from 13 others
What the payments were for
- Consulting fees$1,2389%
- Travel & lodging$3,45424%
- Food & beverage$9,58367%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 13 | $5,180 |
| AbbVie | 37 | $3,816 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $703 |
| Gilead | 6 | $673 |
| E.r. Squibb & Sons, L.L.C. | 6 | $608 |
| Lilly USA, LLC | 5 | $556 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $552 |
| Ferring Pharmaceuticals Inc. | 3 | $386 |
| Pfizer | 3 | $313 |
| Nestle Healthcare Nutrition Inc. | 3 | $313 |
| Johnson & Johnson | 2 | $246 |
| Bristol Myers Squibb | 2 | $159 |
| QOL Medical, LLC | 1 | $128 |
| Regeneron | 1 | $127 |
| Janssen Scientific Affairs, LLC | 1 | $118 |
| Insulet Corporation | 1 | $114 |
| Regeneron Healthcare Solutions, Inc. | 1 | $110 |
| Merit Medical Systems Inc | 1 | $104 |
| Medtronic | 2 | $69 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,274 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 57 | $1,509,820 |
| CreonLipase/Protease/Amylase | 12 | $40,524 |
| Mesalamine | 25 | $26,976 |
| LinzessLinaclotide | 33 | $22,166 |
| Mesalamine ErMesalamine | 17 | $7,494 |
| Balsalazide Disodium | 18 | $1,941 |
| CholestyramineCholestyramine (With Sugar) | 23 | $1,581 |
| Budesonide DrBudesonide | 17 | $1,270 |
| Pantoprazole Sodium | 42 | $928 |
| LoperamideLoperamide Hcl | 16 | $480 |
| Azathioprine | 11 | $347 |
| Omeprazole | 36 | $318 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 15 | $224 |
| Famotidine | 11 | $198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $246 | $1,509,82057 claims |
| AbbVieCreon, Linzess | $3,816 | $62,69045 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.
Other family in Scottsdale
- Kaitlyn LouchheimScottsdale$208K
- Jennifer PrinceScottsdale$76K
- Camilla BinksScottsdale$62K
- Jessica TapiaScottsdale$36K
- Dawn MougelScottsdale$34K
- Keegan RussellScottsdale$28K
- Jamie HowardScottsdale$14K
- Sharon MagalonaMesa$441K
- Angela GoldenMunds Park$378K
- Kimberly HallaPhoenix$332K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.